CAH Quote, Financials, Valuation and Earnings

Cencora has a net margin of 0.92% compared to Cardinal Health's net margin of 0.95%. Cardinal Health's return on equity of -- beat Cencora's return on equity of 183.42%.

Cardinal Health has a consensus price target of $176.41, signalling upside risk potential of 9.5%. On the other hand Cencora has an analysts' consensus of $324.30 which suggests that it could grow by 8.89%. Given that Cardinal Health has higher upside potential than Cencora, analysts believe Cardinal Health is more attractive than Cencora.

Cardinal Health has a beta of 0.675, which suggesting that the stock is 32.48% less volatile than S&P 500. In comparison Cencora has a beta of 0.571, suggesting its less volatile than the S&P 500 by 42.922%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.26%. Cencora offers a yield of 0.73% to investors and pays a quarterly dividend of $0.55 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are smaller than Cencora quarterly revenues of $75.5B. Cardinal Health's net income of $506M is lower than Cencora's net income of $717.9M. Notably, Cardinal Health's price-to-earnings ratio is 25.13x while Cencora's PE ratio is 34.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.18x versus 0.19x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

Henry Schein has a net margin of 0.92% compared to Cardinal Health's net margin of 3.47%. Cardinal Health's return on equity of -- beat Henry Schein's return on equity of 8.28%.

Cardinal Health has a consensus price target of $176.41, signalling upside risk potential of 9.5%. On the other hand Henry Schein has an analysts' consensus of $76.42 which suggests that it could grow by 10.25%. Given that Henry Schein has higher upside potential than Cardinal Health, analysts believe Henry Schein is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.675, which suggesting that the stock is 32.48% less volatile than S&P 500. In comparison Henry Schein has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.426%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.26%. Henry Schein offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Henry Schein pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are larger than Henry Schein quarterly revenues of $3.2B. Cardinal Health's net income of $506M is higher than Henry Schein's net income of $110M. Notably, Cardinal Health's price-to-earnings ratio is 25.13x while Henry Schein's PE ratio is 21.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.18x versus 0.69x for Henry Schein. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of 0.92% compared to Cardinal Health's net margin of 1.39%. Cardinal Health's return on equity of -- beat McKesson's return on equity of --.

Cardinal Health has a consensus price target of $176.41, signalling upside risk potential of 9.5%. On the other hand McKesson has an analysts' consensus of $767.17 which suggests that it could grow by 7.19%. Given that Cardinal Health has higher upside potential than McKesson, analysts believe Cardinal Health is more attractive than McKesson.

Cardinal Health has a beta of 0.675, which suggesting that the stock is 32.48% less volatile than S&P 500. In comparison McKesson has a beta of 0.482, suggesting its less volatile than the S&P 500 by 51.795%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.26%. McKesson offers a yield of 0.4% to investors and pays a quarterly dividend of $0.71 per share. Cardinal Health pays 58.57% of its earnings as a dividend. McKesson pays out 10.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are smaller than McKesson quarterly revenues of $90.8B. Cardinal Health's net income of $506M is lower than McKesson's net income of $1.3B. Notably, Cardinal Health's price-to-earnings ratio is 25.13x while McKesson's PE ratio is 27.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.18x versus 0.26x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple has a net margin of 0.92% compared to Cardinal Health's net margin of --. Cardinal Health's return on equity of -- beat Pineapple's return on equity of --.

Cardinal Health has a consensus price target of $176.41, signalling upside risk potential of 9.5%. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Cardinal Health has higher upside potential than Pineapple, analysts believe Cardinal Health is more attractive than Pineapple.

Cardinal Health has a beta of 0.675, which suggesting that the stock is 32.48% less volatile than S&P 500. In comparison Pineapple has a beta of 35.438, suggesting its more volatile than the S&P 500 by 3443.784%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.26%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are larger than Pineapple quarterly revenues of --. Cardinal Health's net income of $506M is higher than Pineapple's net income of --. Notably, Cardinal Health's price-to-earnings ratio is 25.13x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.18x versus 81.14x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.